Cas:138485-30-0 dimethyl 2-(4-fluorophenyl)propanedioate manufacturer & supplier

We serve Chemical Name:dimethyl 2-(4-fluorophenyl)propanedioate CAS:138485-30-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

dimethyl 2-(4-fluorophenyl)propanedioate

Chemical Name:dimethyl 2-(4-fluorophenyl)propanedioate
CAS.NO:138485-30-0
Synonyms:2-(4-fluorophenyl)-propanedioic acid 1,3-dimethyl ester
Molecular Formula:C11H11FO4
Molecular Weight:226.20100
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:52.60000
Exact Mass:226.06400
LogP:1.25530

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2-(4-fluorophenyl)-propanedioic acid 1,3-dimethyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(4-fluorophenyl)-propanedioic acid 1,3-dimethyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(4-fluorophenyl)-propanedioic acid 1,3-dimethyl ester Use and application,2-(4-fluorophenyl)-propanedioic acid 1,3-dimethyl ester technical grade,usp/ep/jp grade.


Related News: Once they have decided how to make the compound, our staff in the production department manufacture a high quantity of APIs using the large reactors in our plant. dimethyl 2-(4-fluorophenyl)propanedioate manufacturer GlaxoSmithKline (GSK) is at the bottom of the top 20 list with the lowest percentage R&D spend/annual revenue at 12%.�� dimethyl 2-(4-fluorophenyl)propanedioate supplier GlaxoSmithKline (GSK) is at the bottom of the top 20 list with the lowest percentage R&D spend/annual revenue at 12%.�� dimethyl 2-(4-fluorophenyl)propanedioate vendor For example, there are concerns that PFAS’ effect on the thyroid could lead to thyroid cancer, van Gerwen said. dimethyl 2-(4-fluorophenyl)propanedioate factory Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.